Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar:32:78-84.
doi: 10.1016/j.jgar.2023.01.003. Epub 2023 Jan 26.

Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales

Agnès B Jousset  1 , Sandrine Bernabeu  1 , Cécile Emeraud  2 , Rémy A Bonnin  1 , Alexandra Lomont  3 , Jean Ralph Zahar  3 , Audrey Merens  4 , Christophe Isnard  5 , Nathalie Soismier  6 , Eric Farfour  7 , Vincent Fihman  8 , Nicolas Yin  9 , Olivier Barraud  10 , Hervé Jacquier  11 , Anne-Gaëlle Ranc  12 , Frédéric Laurent  12 , Stéphane Corvec  13 , Louise Ruffier d'Epenoux  13 , Emmanuelle Bille  14 , Nicolas Degand  15 , Chloé Plouzeau  16 , Thomas Guillard  17 , Vincent Cattoir  18 , Asaf Mizrahi  19 , Antoine Grillon  20 , Frédéric Janvier  21 , Cécile Le Brun  22 , Marlène Amara  23 , Mathilda Bastide  23 , Alban Lemonnier  24 , Laurent Dortet  25 ; GMC-study Group
Affiliations
Free article

Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales

Agnès B Jousset et al. J Glob Antimicrob Resist. 2023 Mar.
Free article

Abstract

Objectives: Ceftolozane-tazobactam (C/T) proved its efficacy for the treatment of infections caused by non-carbapenemase producing Pseudomonas aeruginosa and Enterobacterales. Here, we aimed to provide susceptibility data on a large series of Enterobacterales since the revision of EUCAST categorization breakpoints in 2020.

Methods: First, C/T susceptibility was determined on characterized Enterobacterales resistant to third generation cephalosporins (3GCs) (extended spectrum β-lactamase [ESBL] production or different levels of AmpC overexpression) (n = 213) and carbapenem-resistant Enterobacterales (CRE) (n = 259), including 170 carbapenemase producers (CPE). Then, 1632 consecutive clinical Enterobacterales responsible for infection were prospectively collected in 23 French hospitals. C/T susceptibility was determined by E-test® (biomérieux) and broth microdilution (BMD) (Sensititre™, Thermo Scientific) to perform method comparison.

Results: Within the collection isolates, 88% of 3GC resistant strains were susceptible to C/T, with important variation depending on the resistance mechanism: 93% vs. 13% susceptibility for CTX-M and SHV-ESBL producers, respectively. Only 20% of the CRE were susceptible to C/T. Among CPE, 80% of OXA-48-like producers were susceptible to C/T, whereas all metallo-β-lactamase producers were resistant. The prospective study revealed that 95.6% of clinical isolates were susceptible to C/T. Method comparison performed on these 1632 clinical isolates demonstrated 99% of categorization agreement between MIC to C/T determined by E-test® in comparison with the BMD (reference) and only 74% of essential agreement.

Conclusion: Overall, C/T showed good activity against wild-type Enterobacterales, AmpC producers, and ESBL-producing Escherichia coli but is less active against ESBL-producing Klebsiella pneumoniae, and CRE. E-test® led to an underestimation of the MICs in comparison to the BMD reference.

Keywords: Carbapenemase; Ceftolozane-tazobactam; ESBL; Enterobacterales; Epidemiology; France; MIC.

PubMed Disclaimer

Publication types

MeSH terms